Tirzepatide Works For Weight Loss, But May Be Pricey; Questions Over Diabetes Drug’s Power Against Dementia
Read about the biggest pharmaceutical developments and pricing stories from the past week in KHN's Prescription Drug Watch roundup.
NBC News:
What To Know About The New Weight Loss Drug Tirzepatide. Will It Be Affordable?
An Eli Lilly drug if approved for weight loss could become the best-selling drug of all time, but concerns are mounting about who will actually be able to afford it. (Lovelace, Jr. 1/1)
Bay Area News Group:
Can Diabetes Drug Metformin Really Slow Aging, Reduce Dementia?
Metformin, a common medication to control diabetes, has become the controversial darling of tech’s health-conscious digerati who are enticed by preliminary research suggesting it might help promote longevity, reduce dementia and prevent a whole host of other conditions – including, most recently, long COVID. (Krieger, 1/3)
FiercePharma:
Unicycive's Pivotal Trial Of Takeda Kidney Drug Rival Hits Goal
Unicycive Therapeutics has laid the groundwork for entering a market targeted by Sanofi and Takeda, posting pivotal bioequivalence data on a candidate designed to improve compliance with kidney disease treatment regimens. (Taylor, 1/3)
The Boston Globe:
Drug Companies Set Sights On New COVID Medicines To Boost Depleted Arsenal
It was not that long ago that the medical community had a small arsenal of new drugs to prevent and treat COVID-19 in people most susceptible to severe disease. But the arrival of new variants, as well as the loss of two treatments for immunocompromised people, has amped up the urgency to develop a stronger generation of medicines. (Cross, 12/28)
